How a Medicine Joins the ARTG

Roughly 600 prescription medicines are added to or varied on the Australian Register of Therapeutic Goods each year. Cannabis-derived medicines have been chasing that number since 2016, and the gap between "approved overseas" and "registered here" remains surprisingly wide. The question of how a medicine joins the ARTG comes up constantly, usually from people who've just discovered that a medicine available in Canada or the UK isn't listed here, and want to understand why.

The short version is that registration is a quality, safety, and efficacy hurdle, not a customs one. Let's walk through what that actually means in practice.

What the ARTG is, and what it isn't

The Australian Register of Therapeutic Goods (ARTG) is a public database maintained by the Therapeutic Goods Administration. Every medicine, medical device, or biological product that is legally supplied in Australia must either appear on the ARTG or qualify for an explicit exemption. There is no third option. If you want the wider picture of the regulator behind the register, the article on the Therapeutic Goods Administration explained covers how the TGA is organised, and the TGA website is the official starting point.

Being on the register doesn't mean a medicine is available at your local pharmacy. It means the TGA has evaluated, to a defined standard, the evidence submitted by a sponsor and concluded the product meets requirements for quality, safety, and efficacy. The registration is then linked to a sponsor (usually the company that applied), a specific formulation, specific indications, and specific labelling. Change any of those materially, and you're looking at a new or varied entry.

That linkage is easy to overlook. A register entry is not a general endorsement of a molecule or a plant. It is a record about one product, made by one sponsor, supplied in one form, for stated purposes. Two products containing the same active ingredient can have quite different entries, and a difference in the manufacturing site or the dosage form can matter to the regulator even when it looks trivial to everyone else. For a closer look at the difference between products that are on the register and those that are not, see the ARTG: registered vs unregistered medicines.

For cannabis-derived medicines specifically, scheduling under the Poisons Standard (the document formally known as the Standard for the Uniform Scheduling of Medicines and Poisons, or SUSMP) runs alongside ARTG status. A product can be ARTG-registered and still require a Schedule 8 controlled drug prescription, which is what applies to most THC-containing medicines. Cannabidiol products meeting the low-dose criteria under Schedule 3 occupy a different lane; but even those went through a formal TGA scheduling process before any pharmacist could hand one over the counter. The scheduling system has its own explainer in the Poisons Standard (SUSMP) explained.

How a medicine joins the ARTG: the three registration pathways

The TGA runs two main evaluation pathways for prescription medicines, plus a separate route for listed (lower-risk) products. Understanding which lane a cannabis medicine falls into determines almost everything about cost, timeline, and evidence requirements. Choosing the wrong lane is one of the more common misconceptions outsiders hold: a sponsor doesn't pick the pathway it would like, it applies for the one that matches the risk profile of the product.

Registered medicines, the full evaluation route. This is the pathway for higher-risk products, including all controlled substances and most prescription-only items. The sponsor lodges a dossier, think of it as an evidence package, often running to tens of thousands of pages; covering chemistry and manufacturing data, pre-clinical toxicology, and human clinical trial results. The TGA's evaluation team works through that dossier, typically over 12 to 18 months for a standard application. The sponsor pays an evaluation fee; as of the 2024–25 fee schedule these run into six figures for a full Category 1 application.

Those timeframes and fees are a large part of why small sponsors struggle. A dossier of that size has to be assembled, quality-checked and kept consistent across every module before it is even lodged, and questions from evaluators during the process can send the sponsor back to the laboratory or the clinic for more data.

Listed medicines, the lower-risk route. Listed products (ARTG entries beginning with "AUST L") are generally complementary medicines making only low-level claims. The sponsor self-certifies compliance against a list of permitted ingredients and indications; the TGA audits rather than pre-evaluates. Very few cannabis products qualify here, because cannabinoids are not currently on the permitted ingredients list for listed medicines with any meaningful indication.

The word "self-certifies" trips people up. It doesn't mean there is no oversight; it means the checking happens after the product is on the market rather than before. The sponsor still carries legal responsibility for what it certified, and what such products may say is tightly constrained, which is why the advertising rules for therapeutic goods matter so much for anything on this lane.

Biosimilars and generic pathways. A generic applicant can reference an already-registered "innovator" product's clinical data and submit an abridged dossier, relying on demonstrated bioequivalence rather than full trial programs. This matters for cannabis because if one full-spectrum oral product is registered for a given indication, a later applicant with a comparable formulation may be able to follow an abridged route; though the pharmacokinetics of cannabis extracts are notoriously variable, and proving bioequivalence is genuinely difficult. Bioavailability data across different oral formulations, inhalation products, and the like can diverge considerably.

What the evidence dossier must cover

The TGA follows the Common Technical Document (CTD) format, the same international template used by regulators in the EU, US, Canada, and Japan. Module 3 covers quality (chemistry, manufacturing, controls). Module 4 covers non-clinical (laboratory and animal) data. Module 5 covers clinical data. A shared template is useful because a sponsor can prepare one core package and adapt it for several regulators, and evaluators can find the same kind of information in the same place. The format is described on the Common Technical Document page on Wikipedia for readers who want the structure laid out.

For any medicine containing THC or other controlled cannabinoids, Module 3 carries extra weight. The TGA will want to see detailed characterisation of the extract, not just the primary cannabinoid but the full profile, including minor constituents. If a product is marketed as full-spectrum, the composition needs to be defined and controlled batch-to-batch. That's harder than it sounds when you're working with a botanical extract; natural variation is real, and the analytical chemistry has to account for it. The terminology itself is often used loosely, so what full-spectrum and isolate actually mean is worth reading before you take a label at face value.

Module 5; the clinical evidence, is where most applications for novel cannabis medicines hit friction. The TGA requires adequate and well-controlled clinical trials demonstrating efficacy for the proposed indication. Observational data, case series, and compassionate-use reports are supportive at best; they don't substitute for randomised controlled trial evidence. This is worth saying plainly because there's a persistent belief in some quarters that the TGA is simply being obstructionist about cannabis. I'd argue that's not quite right: the agency is applying the same evidentiary standard it applies to every other medicine, and that standard is demanding by design.

The reason that standard exists is not mysterious. Individual reports of benefit, however sincere, can't separate the effect of a product from natural recovery, expectation, or other changes happening at the same time. Controlled trials with comparison groups are the tool designed to do that separating, and the reasoning is set out in why anecdotes are not evidence.

Why manufacturing evidence carries so much weight

For a cannabis-derived medicine to reach registered status via this route, the sponsor must also demonstrate Good Manufacturing Practice (GMP) compliance, at every site in the supply chain that touches the medicine. That includes overseas cultivation and extraction facilities. The TGA may accept GMP clearances issued by comparable overseas regulators, but it isn't automatic.

GMP is a quality system rather than a single test. It covers how premises are built and maintained, how staff are trained, how materials are received and recorded, how each batch is made and released, and what happens when something goes wrong. The point is to make the product reproducible, so that the tablet or oil evaluated in the dossier is the one that reaches the patient months later. A plant-derived product has more places for variation to creep in than a synthetic one, which is why a break in the chain at any site can stall an otherwise strong application. The licensing side of this is covered in TGA good manufacturing practice licensing.

After registration: scheduling, PBS, and what "approved" really means

ARTG registration and PBS listing are separate decisions made by separate bodies. A medicine can be registered, meaning the TGA is satisfied with quality, safety, and efficacy evidence; and still not be subsidised under the Pharmaceutical Benefits Scheme. The Pharmaceutical Benefits Advisory Committee (PBAC) conducts its own cost-effectiveness assessment, and the minister makes the final call on PBS listing. For patients paying out of pocket, ARTG-registered cannabis medicines carry price tags that vary widely by formulation and dose.

Scheduling determines who can prescribe or supply the medicine and under what conditions. Most THC-containing registered products sit at Schedule 8, which means controlled drug prescription rules apply, state and territory permit requirements, prescription limits, and dispensing record-keeping. Schedule 4 applies to most CBD-dominant registered medicines above the low-dose threshold. The practical differences between the two categories are laid out in Schedule 4 vs Schedule 8: what they mean, and the glossary entry for Schedule 4 (prescription only) gives the short definition.

For medicines not yet registered, the Special Access Scheme and the Authorised Prescriber pathway exist as lawful routes to access unapproved therapeutic goods, but that's a separate article, and the mechanics are quite different from what I've described here. The legal footing for those routes is explained in unapproved therapeutic goods: the legal basis, and the term often used for products still in trials is unpacked in what "investigational medicine" really means.

Common misunderstandings about registration

A few errors turn up again and again. The first is treating "approved" as a single yes-or-no label. In practice a product can be registered but not subsidised, registered but tightly scheduled, or registered for one stated indication and nothing else. Each of those is a different regulatory fact, made by a different decision-maker.

The second is assuming that overseas approval carries across. Comparable regulators sometimes share information, and the TGA may rely on some overseas clearances, particularly for manufacturing sites, but a foreign approval does not place a product on the Australian register. A sponsor still has to apply here.

The third is reading a label or a website as proof of registration. Whether a product is on the ARTG is a question the public register can answer; a marketing claim can't. Checking the entry, and checking that it matches the product, sponsor and stated use, is the sensible habit. I'd go further and say that anyone who can't point to an entry when asked should be treated with caution, whatever else they say.

Why registration matters beyond the paperwork

The 2016 cannabinoid scheduling amendments anticipated much of the supply-chain complexity that later played out. The requirement for GMP-compliant manufacturing wasn't an afterthought; it was the hinge on which the whole access model turned. For the wider story of how that change came about, Australia's 2016 medicinal cannabis legalisation is the place to start.

That complexity matters to patients and prescribers in a practical way. An ARTG-registered product comes with a defined, tested formulation. The standardised extract on the label reflects what's in the bottle, with a documented tolerance. Batch records exist. Post-market surveillance obligations attach to the sponsor. None of that is guaranteed for a product accessed outside the registration framework, and the TGA has been increasingly active in enforcement action on that front.

The register, for all its administrative weight, is doing real work. Getting a medicine onto it is genuinely hard. But that hardness is, mostly, the point.

Sources

• Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration (TGA)
• Guidance on the registration of prescription medicines, TGA
• Poisons Standard (SUSMP); Federal Register of Legislation, Australian Government
• Medicinal cannabis, Therapeutic Goods Administration (TGA)

Marcus Hale, Regulatory researcher, TGA & access law